Iterum Therapeutics (ITRM) Q4 2024 earnings summary

Executive summary

• Achieved FDA approval for Orlinva/ORLYNVAH™, the first and only oral penem in the U.S., for treating uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial options, marking the first branded uUTI product in over 25 years.

• Completed pivotal phase 3 ReAssure trial with positive results, leading to NDA resubmission and subsequent approval.

• Initiated a strategic process to sell, license, or otherwise dispose of rights to Orlinva/ORLYNVAH™, with outreach to dozens of pharma companies and financial investors.

• Engaged in pre-commercial activities, including research with payers and physicians, analytics for targeted launch planning, and ongoing outreach to strategic partners.

• Australian patent for sulopenem etzadroxil and probenecid combination expected to issue, expiring in 2039.

Financial highlights

• Total operating expenses were $3.7 million in Q4 and $18.7 million for 2024, down from $11.4 million and $47.5 million in 2023.

• R&D expenses dropped to $1.3 million in Q4 and $10.5 million for 2024, mainly due to completion of the ReAssure trial.

• Net loss (GAAP) was $6.6 million for Q4 and $24.8 million for 2024, both improved from $12.4 million and $38.4 million in 2023.

• Non-GAAP net loss was $3.1 million for Q4 and $17.6 million for 2024, both significantly improved year-over-year.

• Cash and cash equivalents at year-end were $24.1 million, with an additional $4.8 million raised in early 2025.

Outlook and guidance

• Cash resources expected to fund operations into the second half of 2025, including planned pre-commercialization activities and factoring in recent fundraising and note repayment.

• Focus remains on maximizing value from Orlinva/ORLYNVAH™ through a strategic transaction or, if necessary, direct commercialization.